The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in ...
BALTIMORE -- One in five people in the United States struggle with learning or attention disabilities, according to the Learning Disability Association of America. While they can make learning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results